Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21987437 | 0.90 | KDM4E (0.38) | SMYD2SMN1; SMN2TOP2ALMNAMEN1 | |
| SCHEMBL21987438 | 0.90 | KDM4E (0.38) | SMYD2SMN1; SMN2TOP2ALMNAMEN1 | |
| SCHEMBL21987604 | 0.89 | SMYD2 (0.35) | SMYD2RIPK1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL21987310 | 0.80 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL554843 | 0.80 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2LMNA | |
| SCHEMBL19898543 | 0.79 | SMYD2 (0.35) | SMYD2RIPK1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL21987812 | 0.79 | KDM4E (0.40) | LMNAMEN1KMT2A | |
| SCHEMBL2392272 | 0.79 | SMYD2 (0.33) | SMYD2RIPK1 | |
| SCHEMBL21987810 | 0.79 | KDM4E (0.40) | LMNAMEN1KMT2A | |
| SCHEMBL14486195 | 0.78 | SMYD2 (0.36) | SMYD2RIPK1CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | SMYD2 3852/4885RIPK1 2890/4885FKBP1A 2235/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | SMYD2 4324/4885RIPK1 4017/4885FKBP1A 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.